WallStSmart
FOLD

Amicus Therapeutics Inc

NASDAQ: FOLD · HEALTHCARE · BIOTECHNOLOGY

$14.49
+0.00% today

Updated 2026-04-27

Market cap
$4.55B
P/E ratio
P/S ratio
7.17x
EPS (TTM)
$-0.09
Dividend yield
52W range
$6 – $15
Volume
3.5M

Amicus Therapeutics Inc (FOLD) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+74.7%
Last 4 quarters
Revenue YoY growth
+23.7%
Most recent quarter
EPS YoY growth
+11.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+2.3%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+3.7%
2025-11-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-19$0.10+53.8%$14.34$14.34+0.0%
2025-11-04$0.06+100.0%$8.86$9.19+3.7%
2025-07-31$-0.08+27.3%$6.13$6.32+3.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.07$0.10+53.8%$185.21M+23.7%
2025-09-30$0.03$0.06+100.0%$169.06M+19.5%
2025-06-30$-0.11$-0.08+27.3%$154.69M+22.1%
2025-03-31$-0.07$0.03+142.9%$125.25M+13.4%
2024-12-31$0.09$0.09-1.2%$149.71M+30.1%
2024-09-30$-0.01$-0.02-100.0%$141.52M+36.7%
2024-06-30$-0.06$-0.05+16.7%$126.67M+34.0%
2024-03-31$-0.07$-0.16-128.6%$110.40M
2023-12-31$-0.06$-0.11-83.3%$115.08M
2023-09-30$-0.08$-0.07+12.5%$103.50M
2023-06-30$-0.12$-0.15-25.0%$94.50M

Frequently asked questions

Has Amicus Therapeutics Inc beaten earnings estimates?
Amicus Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +74.7% over the last 3 quarters.
How does FOLD stock react to earnings?
FOLD stock has moved an average of +2.3% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Amicus Therapeutics Inc's revenue growth rate?
Amicus Therapeutics Inc reported year-over-year revenue growth of +23.7% in its most recent quarter, with EPS growing +11.1% year-over-year.